SCHEMBL16617582

SCHEMBL16617582

O=C(NC(C(=O)C1CCCCC1C(=O)O)c1ccc(Br)cc1)c1cccc(Cl)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.38
RAB9A P51151 1/20 0.38
P2RX7 Q99572 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
GRK2 P25098 1/20 0.37
CASP6 P55212 1/20 0.37
CASP8 Q14790 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
POLB P06746 1/20 0.37
KAT6A Q92794 1/20 0.36
KMT2A Q03164 2/20 0.36
KEAP1 Q14145 1/20 0.35
NFE2L2 Q16236 1/20 0.35
SLC6A9 P48067 3/20 0.35
CHRM1 P11229 1/20 0.34
PYGL P06737 2/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CNR1 P21554 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16618134 0.81 P2RX7 (0.36) P2RX7POLBKAT6ASLC6A9CHRM1
SCHEMBL16618154 0.76 TAS1R3 (0.41) L3MBTL1GRK2CASP6CASP8CTDSP1
SCHEMBL16617787 0.73 POLB (0.43) CYP2C19L3MBTL1GRK2CASP6CASP8
SCHEMBL16617722 0.69 HSD11B1 (0.39) L3MBTL1GRK2CASP6CASP8CTDSP1
SCHEMBL16617527 0.69 L3MBTL1 (0.44) RAB9AL3MBTL1KMT2AMEN1
SCHEMBL16638073 0.69 L3MBTL1 (0.44) RAB9AL3MBTL1KMT2AMEN1
SCHEMBL16617692 0.69 GRK2 (0.42) CYP2C19RAB9AL3MBTL1GRK2CASP6
SCHEMBL16617817 0.68 CYP3A4 (0.48) CYP2C19RAB9APOLBKMT2AMEN1
SCHEMBL16617819 0.68 CYP3A4 (0.48) CYP2C19RAB9APOLBKMT2AMEN1
SCHEMBL16617792 0.66 CYP3A4 (0.44) POLBKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3055314-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2018-09-12 EP disclosed
US-9458181-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-04 US disclosed
EP-3055314-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054089-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ CYP2C19 3731/4885RAB9A 477/4885P2RX7 4542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.